All In Biotech

Drug Trial Radar · NCT05364073

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

160

Actual

Start

Jun 30, 2022

Primary completion

Jun 3, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
ArriVent BioPharma, Inc.Industry
Sponsor type
Industry
First posted
May 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) mutations. Patients will be enrolled into one of 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).

Conditions

  • Non-Small Cell Lung Cancer (NSCLC)
  • Metastatic Non-Small Cell Lung Cancer
  • Advanced Non-Small Cell Lung Cancer
  • HER2 Exon 20 Mutations
  • EGFR Exon 20 Mutations
  • EGFR Uncommon Mutations, Including G719X and S768I

Interventions

  • FurmonertinibDrug

    Furmonertinib tablet

  • FurmonertinibDrug

    Furmonertinib tablet

  • FurmonertinibDrug

    Furmonertinib tablet

  • FurmonertinibDrug

    Furmonertinib tablet

  • FurmonertinibDrug

    Furmonertinib tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1: Number of incidence and severity of adverse events (AEs) as a measure of safety and tolerability of FurmonertinibTime frame: Up to 36 months after first dose
  2. Stage 2: Overall Response Rate (ORR)Time frame: Up to 36 months after first dose

Locations

42 sites in 11 countries. Site status is shown where the registry gives one.

  • ArriVent Investigative Site

    Prescott, Arizona

  • ArriVent Investigative Site

    Sacramento, California

  • ArriVent Investigative Site

    Whittier, California

  • ArriVent Investigative Site

    Celebration, Florida

  • ArriVent Investigative Site

    Detroit, Michigan

  • ArriVent Investigative Site

    Houston, Texas

  • ArriVent Investigative Site

    Fairfax, Virginia

  • ArriVent Investigative Site

    Blacktown, New South Wales, Australia

  • ArriVent Investigative Site

    St Leonards, New South Wales, Australia

  • ArriVent Investigative Site

    Heidelberg, Victoria, Australia

  • Arrivent Investigative Site

    Edmonton, Canada

  • Arrivent Investigative Site

    Toronto, Canada

  • Allist Investigative Site

    Hefei, Anhui, China

  • Allist Investigative Site

    Beijing, Beijing Municipality, China

  • Allist Investigative Site

    Chaoyang, Beijing Municipality, China

  • Allist Investigative Site

    Chongqing, Chongqing Municipality, China

  • Allist Investigative Site

    Harbin, Heilongjiang, China

  • Allist Investigative Site

    Zhengzhou, Henan, China

  • Allist Investigative Site

    Zhengzhou, Henan, China

  • Allist Investigative Site

    Wuhan, Hubei, China

  • Allist Investigative Site

    Xuzhou, Jiangsu, China

  • Allist Investigative Site

    Nanchang, Jianxi, China

  • Allist Investigative Site

    Changchun, Jilin, China

  • Allist Investigative Site

    Jinan, Shandong, China

  • Allist Investigative Site

    Jinan, Shandong, China

  • Allist Investigative Site

    Taiyuan, Shanxi, China

  • ArriVent Investigative Site

    Lyon, France

  • Arrivent Investigative Site

    Toulouse, France

  • Arrivent Investigative Site

    Villejuif, France

  • ArriVent Investigative Site

    Medolla, Italy

  • ArriVent Investigative Site

    Chiba, Chiba, Japan

  • Arrivent Investigative Site

    Ōsaka-sayama, Osaka, Japan

  • Arrivent Investigative Site

    Chūō, Tokyo, Japan

  • Arrivent Investigative Site

    Koto-Ku, Tokyo, Japan

  • Arrivent Investigative Site

    Amsterdam, North Holland, Netherlands

  • Arrivent Investigative Site

    Gwangju, South Korea

  • Arrivent Investigative Site

    Seoul, South Korea

  • ArriVent Investigative Site

    Barcelona, Spain

  • ArriVent Investigative Site

    Madrid, Spain

  • ArriVent Investigative Site

    Madrid, Spain

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.